Thursday, September 27, 2012
Pacira Pharmaceuticals Inc., of Parsippany, N.J., said it started a Phase II/III pivotal trial of pain drug Exparel (bupivacaine liposome injectable suspension) administered as a single-dose injection femoral nerve block for total knee arthroplasty surgery.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.